Literature DB >> 19151962

[Co-morbidities in psoriasis vulgaris].

W-H Boehncke1, C Buerger, S Boehncke.   

Abstract

Epidemiologic data document not only a higher prevalence of joint involvement among psoriasis patients than previously thought, but also an association with numerous other diseases, including depression, smoking, alcoholism, Crohn's disease, and metabolic syndrome. The resulting increased cardiovascular mortality is of particular clinical importance, and its pathogenetic link as a complication of the psoriatic inflammation is well recognized. Thus, we need to re-invent the management of psoriasis: Dermatologists are not only the sentinel regarding the early diagnosis of psoriatic arthritis, but also of metabolic complications such as dyslipidemia or diabetes. Moreover, they need to keep in mind interactions between (systemic) anti-psoriatic drugs and the co-medication of their patients as well as possible consequences of these co-medications on the course of psoriasis. To successfully accomplish this mission, a comprehensive management concept and ground-breaking research are urgently needed.

Entities:  

Mesh:

Year:  2009        PMID: 19151962     DOI: 10.1007/s00105-008-1663-3

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  28 in total

1.  Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis.

Authors:  Lennart T H Jacobsson; Carl Turesson; Anders Gülfe; Meliha C Kapetanovic; Ingemar F Petersson; Tore Saxne; Pierre Geborek
Journal:  J Rheumatol       Date:  2005-07       Impact factor: 4.666

Review 2.  Inflammation, stress, and diabetes.

Authors:  Kathryn E Wellen; Gökhan S Hotamisligil
Journal:  J Clin Invest       Date:  2005-05       Impact factor: 14.808

3.  Activated, not resting, platelets increase leukocyte rolling in murine skin utilizing a distinct set of adhesion molecules.

Authors:  Ralf J Ludwig; Jeanette E Schultz; Wolf-Henning Boehncke; Maurizio Podda; Christa Tandi; Fritz Krombach; Holger Baatz; Roland Kaufmann; Ulrich H von Andrian; Thomas M Zollner
Journal:  J Invest Dermatol       Date:  2004-03       Impact factor: 8.551

4.  Disease concomitance in psoriasis.

Authors:  T Henseler; E Christophers
Journal:  J Am Acad Dermatol       Date:  1995-06       Impact factor: 11.527

5.  The inflammatory response in mild and in severe psoriasis.

Authors:  P Rocha-Pereira; A Santos-Silva; I Rebelo; A Figueiredo; A Quintanilha; F Teixeira
Journal:  Br J Dermatol       Date:  2004-05       Impact factor: 9.302

6.  C-reactive protein and alpha2-macroglobulin plasma activity in medium-severe and severe psoriasis.

Authors:  G Chodorowska; D Wojnowska; M Juszkiewicz-Borowiec
Journal:  J Eur Acad Dermatol Venereol       Date:  2004-03       Impact factor: 6.166

7.  Psoriasis patients show signs of insulin resistance.

Authors:  S Boehncke; D Thaci; H Beschmann; R J Ludwig; H Ackermann; K Badenhoop; W-H Boehncke
Journal:  Br J Dermatol       Date:  2007-10-04       Impact factor: 9.302

8.  Comedication related to comorbidities: a study in 1203 hospitalized patients with severe psoriasis.

Authors:  S Gerdes; V A Zahl; H Knopf; M Weichenthal; U Mrowietz
Journal:  Br J Dermatol       Date:  2008-11       Impact factor: 9.302

9.  Tumor necrosis factor-alpha induces insulin resistance in endothelial cells via a p38 mitogen-activated protein kinase-dependent pathway.

Authors:  Guolian Li; Eugene J Barrett; Matthew O Barrett; Wenhong Cao; Zhenqi Liu
Journal:  Endocrinology       Date:  2007-04-19       Impact factor: 4.736

10.  Tumor necrosis factor-alpha inhibits endothelial nitric-oxide synthase gene promoter activity in bovine aortic endothelial cells.

Authors:  Hope D I Anderson; Dolkun Rahmutula; David G Gardner
Journal:  J Biol Chem       Date:  2003-10-27       Impact factor: 5.157

View more
  3 in total

Review 1.  [Comorbidities and psoriasis. Impact on clinical practice].

Authors:  S Gerdes; U Mrowietz
Journal:  Hautarzt       Date:  2012-03       Impact factor: 0.751

2.  [Comorbidities in psoriatic arthritis].

Authors:  W-H Boehncke; S Boehncke
Journal:  Z Rheumatol       Date:  2013-10       Impact factor: 1.372

3.  Association of ERAP1 gene polymorphisms with the susceptibility to psoriasis vulgaris: A case-control study.

Authors:  Yanjie Fu; Xiuyan Li; Yuanzheng Chen; Rongpeng Liu; Renheng Wang; Nan Bai
Journal:  Medicine (Baltimore)       Date:  2018-10       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.